5-aminolevulinic acid [1], phenothiazines ---> SmPC of [1] of EMA
Concomitant use of medicinal products with known phototoxic or photoallergic potential may enhance the phototoxic reaction to photodynamic therapy.
Ability to drive, phenothiazines [2] ---> SmPC of [2] of eMC
Phenothiazines may impair alertness and induce drowsiness especially at the start of treatment.
Acarbose, phenothiazines
The combined active ingredient with acarbose may cause hyperglycaemia, what may attenuate the acarbose effects. Monitorization of the blood-sugar concentration is recommended
ACE inhibitors, phenothiazines ---> SmPC of [fluphenazine] of eMC
Concurrent use of phenothiazines and ACE inhibitors may result in severe postural hypotension.
Acebutolol, phenothiazines
Concomitant administration may increase the blood pressure lowering effect of beta-blockers.
Adrenaline, phenothiazines ---> SmPC of [articaine/epinephrine] of eMC
Phenothiazines may decrease or reverse the pressor effect of epinephrine.
AIIRA, phenothiazines ---> SmPC of [fluphenazine] of eMC
Concurrent use of phenothiazines and angiotensin II antagonists may result in severe postural hypotension.
Alcohol, phenothiazines [2] ---> SmPC of [2] of eMC
The sedative effects of phenothiazines may be intensified (additively) by alcohol
Algeldrate/magnesium hydroxide, phenothiazines
The co-administration of aluminium-containing antacids with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 2 hours
Alizapride, phenothiazines
Increased effect of the phenothiazine
Almasilate [1], phenothiazines ---> SmPC of [1] of eMC
The antacid can decrease the gastrointestinal absorption of phenothiazine
Alpha-methyldopa, phenothiazines
Decreased hypotensive effect
Aluminium hydroxide, phenothiazines
The co-administration of aluminium-containing antacids with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 2 hours
Aluminium oxide/magnesium hydroxide, phenothiazines
The co-administration of aluminium-containing antacids with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 2 hours
Aluminium, phenothiazines ---> SmPC of [levomepromazine] of eMC
The co-administration may decrease the absorption of phenothiazine. Separate administration by at least 2 hours
Amantadine, phenothiazines
The dopamine antagonist should be avoided with amantadine
Amfepramone, phenothiazines
Total or partial suppression of the central stimulant and anorexigenic of amfepramone by neuroleptic drugs
Amifampridine [1], phenothiazines ---> SmPC of [1] of EMA
The concomitant use of amifampridine and substances known to lower the epileptic threshold leads to an increased risk of seizures
Amikacine, phenothiazines
Phenothiazines may mask the ototoxicity symptoms of aminoglycoside antibiotics
Amiloride/hydrochlorothiazide, phenothiazines
The hypotensive effect of amiloride/hydrochlorothiazide can be enhanced by phenothiazines
Aminoglycoside antibiotics, phenothiazines ---> SmPC of [amikacine] of eMC
Phenothiazines may mask the ototoxicity symptoms of aminoglycoside antibiotics
Amiodarone, phenothiazines
The use of amiodarone with other antiarrhythmics or arrhytmogenic medicinal products may increase the incidence of cardiac arrhythmias and should be avoided
Amphetamine, phenothiazines
Concurrent use of phenothiazines and amfetamine/anorectic agents may produce antagonistic pharmacological effects.
Anaesthetics, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Anorexics, phenothiazines
Concurrent use of phenothiazines and amfetamine/anorectic agents may produce antagonistic pharmacological effects.
Antacids, phenothiazines ---> SmPC of [alimemazine] of eMC
The antacid can decrease the gastrointestinal absorption of phenothiazine
Anticholinergics, phenothiazines
The combination with phenothiazines may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Anticholinergics, phenothiazines
The combination may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Anticoagulants, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may impair the action of anti-convulsants.
Antidepressants with serotonergic effect, phenothiazines ---> SmPC of [vortioxetine] of EMA
Caution is advised when co-administrating medicines capable of lowering the seizure threshold.
Antidepressants, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Antidiabetics, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may impair the control of diabetes.
Antidiarrheals, phenothiazines ---> SmPC of [alimemazine] of eMC
The antidiarrhoic agent can decrease the gastrointestinal absorption of oral administered phenothiazine
Antiepileptics, phenothiazines
Phenothiazines may decrease the seizure threshold
Antihistamines, phenothiazines
The combination with phenothiazines may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Antihypertensives, phenothiazines
The hypotensive effect of most antihypertensive drugs especially alpha adrenoceptor blocking agents may be exaggerated by neuroleptics.
Articaine/epinephrine, phenothiazines
Phenothiazines may decrease or reverse the pressor effect of epinephrine.
Atenolol, phenothiazines
Concomitant use of atenolol with antihypertensive agents as well as other drugs with blood pressure lowering potential may increase the risk of hypotension.
Atenolol/chlortalidone, phenothiazines
Enhanced antihypertensive effect
Atenolol/nifedipine [1], phenothiazines ---> SmPC of [1] of eMC
Concomitant use of atenolol with antihypertensive agents as well as other drugs with blood pressure lowering potential may increase the risk of hypotension.
Atomoxetine, phenothiazines
Seizures are a potential risk with atomoxetine. Caution is advised with concomitant use of medicinal drugs which are known to lower the seizure threshold
Atropine [1], phenothiazines ---> SmPC of [1] of eMC
Increased risk of atropinic adverse effects (urinary retention, constipation, dry mouth)
Azithromycin, phenothiazines
The simultaneous use is contraindicated.
Barbiturates, phenothiazines ---> SmPC of [fluphenazine] of eMC
Concomitant use of barbiturates with phenothiazines may result in reduced serum levels of both drugs, and an increased response if one of the drugs is withdrawn.
Beclometasone/formoterol/glycopyrronium [1], phenothiazines ---> SmPC of [1] of EMA
Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias.
Bendroflumethiazide, phenothiazines
The co-administration may increase the antihypertensive effects
Benzodiazepines, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Betablockers, phenothiazines ---> SmPC of [nebivolol] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Betaxolol, phenothiazines
The combination may cause strong hypotension
Bisoprolol [1], phenothiazines ---> SmPC of [1] of eMC
Concomitant use of bisoprolol with antihypertensive agents as well as with other medicinal products with blood pressure lowering potential may increase the risk of hypotension.
Breast-feeding, phenothiazines
Phenothiazines may be excreted in milk: breast feeding should be suspended during treatment.
Bromocriptine [1], phenothiazines ---> SmPC of [1] of eMC
Dopamine antagonists may reduce the prolactin-lowering and antiparkinsonian effects of bromocriptine.
Budesonide/formoterol [1], phenothiazines ---> SmPC of [1] of EMA
Concomitant treatment of formoterol with phenothiazines can prolong the QTc-interval and increase the risk of ventricular arrhythmias.
Butylscopolamine [1], phenothiazines ---> SmPC of [1] of eMC
The anticholinergic effect may be intensified by hyoscine butylbromide
Cabergoline [1], phenothiazines ---> SmPC of [1] of eMC
Cabergoline should not be concurrently administered with drugs which have dopamine antagonist activity since these might reduce the therapeutic effect of cabergoline.
Calcium, phenothiazines ---> SmPC of [levomepromazine] of eMC
The co-administration may decrease the absorption of phenothiazine. Separate administration by at least 2 hours
Carteolol, phenothiazines
The co-administration increases the risk of heart rhythm disorders, particularly torsades de pointes
Carvedilol [1], phenothiazines ---> SmPC of [1] of eMC
Carvedilol may potentiate the effects of medicines with antihypertensive adverse reactions such as phenothiazines
Cathine, phenothiazines
Total or partial suppression of the central stimulant and anorexigenic of cathine by neuroleptic drugs
Celiprolol [1], phenothiazines ---> SmPC of [1] of eMC
Concomitant use may potentiate the orthostatic hypotensive effects of beta blockers.
Chlortalidone, phenothiazines
The co-administration may increase the antihypertensive effects
Cimetidine, phenothiazines
Cimetidine may possibly enhance the effects of phenothiazines
Cinitapride, phenothiazines
Potentiation of phenothiazine effects on the CNS
Cisapride, phenothiazines
The co-administration of cisapride with drugs that may prolong the QT interval and/or induce torsades de pointes is contraindicated
Cisplatin [1], phenothiazines ---> SmPC of [1] of eMC
Simultaneous use of cisplatin and phenothiazines may mask ototoxicity symptoms (such as dizziness and tinnitus).
Citalopram [1], phenothiazines ---> SmPC of [1] of eMC
Co-administration of citalopram with medicinal products that prolong the QT interval is contraindicated
Clebopride, phenothiazines
Potentiation of phenothiazine effects on the CNS
Clomipramine [1], phenothiazines ---> SmPC of [1] of eMC
The risk of QTc prolongation and Torsade de Pointes is likely to be increased if clomipramine is co-administered with other drugs that can cause QTc prolongation. Therefore concomitant use is not recommended
Clonidine, phenothiazines ---> SmPC of [fluphenazine] of eMC
The action of clonidine may be opposed by the phenothiazine
Clopamide, phenothiazines
Increased hypotensive effect
CNS depressants, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Cocaine, phenothiazines
Concurrent use of phenothiazines and cocaine may increase the risk of acute dystonia.
Codeine, phenothiazines
The co-administration may enhance the sedative and respiratory depressor effect
Corticosteroids, phenothiazines ---> SmPC of [perphenazine] of eMC
Phenothiazines may enhance the absorption of corticosteroids
Cyclopentolate, phenothiazines
The effects of antimuscarinic agents may be enhanced by the concomitant administration of other drugs with antimuscarinic properties
Delamanid [1], phenothiazines ---> SmPC of [1] of EMA
Treatment with delamanid should not be initiated in patients with risk factors like taking medicinal products that are known to prolong the QTc interval, unless the possible benefit is considered to outweigh the potential risks.
Dexchlorpheniramine, phenothiazines
Additive anticholinergic effects
Diamorphine [1], phenothiazines ---> SmPC of [1] of eMC
The depressant effects of diamorphine may be exaggerated and prolonged by phenothiazines
Diazoxide, phenothiazines
Diazoxide may potentiate the effect of hypotensive drugs, what cause a further hypotension
Diazoxide, phenothiazines
The phenothiazine may enhance the effect of diazoxide
Digoxin [1], phenothiazines ---> SmPC of [1] of eMC
Phenothiazines may enhance the absorption of digoxin
Disopyramide [1], phenothiazines ---> SmPC of [1] of eMC
Atropine and other anticholinergic drugs, including phenothiazines, may potentiate the atropine-like effects of disopyramide.
Disulfiram, phenothiazines
The intensity of the disulfiram-alcohol reaction may be increased
Dopamine agonists, phenothiazines
Dopamine antagonists, such as phenothiazines, ordinarily should not be administered concurrently with dopamine agonists; these agents may diminish the effectiveness of dopamine agonists
Dopamine antagonists, phenothiazines
The co-administration may enhance the extrapyramidal disorders
Dopamine [1], phenothiazines ---> SmPC of [1] of eMC
Dopamine induced renal and mesenteric vasodilation is antagonised by phenothiazines
Dronedarone [1], phenothiazines ---> SmPC of [1] of EMA
Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias
Droperidol [1], phenothiazines ---> SmPC of [1] of eMC
There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval
Electrolyte imbalance, phenothiazines
Phenothiazines increase the risk of ventricular arrhythmias when given with drugs causing electrolyte imbalances.
Escitalopram [1], phenothiazines ---> SmPC of [1] of eMC
Co-administration of escitalopram with medicinal products that prolong the QT-interval is contraindicated.
Esmolol [1], phenothiazines ---> SmPC of [1] of eMC
Concomitant administration of esmolol and phenothiazines may increase the blood pressure lowering effect.
Fentanyl [1], phenothiazines ---> SmPC of [1] of EMA
The concomitant use of fentanyl with other central nervous system depressants may produce additive depressant effects.
Fluoxetine [1], phenothiazines ---> SmPC of [1] of eMC
Caution is advised in patients taking SSRIs, particularly in concomitant use with oral anticoagulants, drugs known to affect platelet function or other drugs that may increase risk of bleeding as well as in patients with a history of bleeding disorders.
Fluphenazine, phenothiazines [2] ---> SmPC of [2] of eMC
The effect of fluphenazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs and fluphenazine is contraindicated.
Fluvoxamine [1], phenothiazines ---> SmPC of [1] of eMC
Caution is advised in patients taking SSRIs particularly in elderly patients and in patients who concomitantly use drugs known to affect platelet function or drugs that increase risk of bleeding
Formoterol [1], phenothiazines ---> SmPC of [1] of eMC
Caution should be observed in patients treated with drugs that may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia
Formoterol/glycopyrronium/budesonide [1], phenothiazines ---> SmPC of [1] of EMA
Concomitant treatment can prolong the QT interval and increase the risk of ventricular arrhythmias.
Fosphenytoin [1], phenothiazines ---> SmPC of [1] of eMC
Phenothiazines may increase phenytoin serum levels
Gentamicin, phenothiazines
Phenothiazines may mask the ototoxicity symptoms of aminoglycoside antibiotics
Glibenclamide [1], phenothiazines ---> SmPC of [1] of EMA
The co-administration may weaken the hypoglycemic effect
Gliclazide, phenothiazines
The co-administration may weaken the hypoglycemic effect
Glimepiride [1], phenothiazines ---> SmPC of [1] of eMC
Weakening of the blood-glucose-lowering effect and possible hyperglycaemia
Glipizide, phenothiazines
Weakening of the blood-glucose-lowering effect and possible hyperglycaemia
Gliquidone, phenothiazines
Hyperglycemic reactions may occur as expression of weakening effect of gliquidone with gliquidone is co-administered with phenothiazines
Glucocorticoids, phenothiazines
The phenothiazine may enhance the absorption of glucocorticoid
Glycopyrronium [1], phenothiazines ---> SmPC of [1] of EMA
The co-administration of glycopyrronium with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Gonadorelin, phenothiazines [2] ---> SmPC of [2] of eMC
The co-administration may weaken the gonadorelin effect due to increased prolactin
Guanethidine, phenothiazines ---> SmPC of [trifluoperazine] of eMC
The anti-hypertensive action of guanethidine may be reduced by phenothiazine derivatives
Haloperidol, phenothiazines [2] ---> SmPC of [2] of eMC
Concomitant use of haloperidol with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended
Hydrochlorothiazide, phenothiazines
Thiazides may enhance the photosensitizing effects of phenothiazines
Hydroxychloroquine, phenothiazines
Hydroxychloroquine may increase plasma concentrations of phenothiazines
IMAOs, phenothiazines
The concomitant use may prolong or enhance the sedative and anticholinergic effect whether of MAO inhibitor or of phenothiazine
Imipramine [1], phenothiazines ---> SmPC of [1] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Insulin glargin [1], phenothiazines ---> SmPC of [1] of EMA
Reduced blood-glucose-lowering effect
Insulin glargine/lixisenatide [1], phenothiazines ---> SmPC of [1] of EMA
This substance may reduce the blood-glucose-lowering effect.
Insulin glulisin [1], phenothiazines ---> SmPC of [1] of EMA
Possible decrease in blood-glucose-lowering activity
Insulin, phenothiazines
Possible increase of the insulin requirements
Insulin, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may impair the control of diabetes.
Iodixanol, phenothiazines
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
Iohexol, phenothiazines
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
Iomeprol, phenothiazines [2] ---> SmPC of [2] of eMC
Treatment with drugs that lower the seizure threshold should be discontinued 48 hours before the examination. Treatment should not be resumed until 24 hours post-procedure.
Iopamidol, phenothiazines
Medicinal products that reduce the convulsant threshold should be discontinued 48 hours before and up to 24 hours after examination
Isocarboxazid, phenothiazines
Concurrent administration of isocarboxazid with other central nervous system depressants may lead to potentiation of their effects.
Isoniazid, phenothiazines
Isoniazid, enzymatic inhibitor, may increase the plasma levels of phenothiazine
Ketamine [1], phenothiazines ---> SmPC of [1] of eMC
The use of ketamine with other central nervous system (CNS) depressants can potentiate CNS depression and/or increase risk of developing respiratory depression.
Labetalol, phenothiazines [2] ---> SmPC of [2] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Levodopa, phenothiazines ---> SmPC of [levodopa/carbidopa] of EMA
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone), benzodiazepines and isoniazid may reduce the therapeutic effects of levodopa.
Levodopa/carbidopa [1], phenothiazines ---> SmPC of [1] of EMA
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone), benzodiazepines and isoniazid may reduce the therapeutic effects of levodopa.
Levodopa/carbidopa/entacapone, phenothiazines
The combination can decrease the therapeutic effect of levodopa
Levomethadone, phenothiazines
Enhancement of effects and adverse effects, particularly respiratory depression
Lithium, phenothiazines
Serum levels of phenothiazine can be reduced to non-therapeutic concentrations by concurrent administration of lithium. Sleep walking has been described in some patients taking phenothiazines and lithium.
Lofepramine, phenothiazines
Lofepramine may potentiate the effects of anticholinergic drugs on the central nervous system, eye, bowel and bladder.
Loxapine [1], phenothiazines ---> SmPC of [1] of EMA
Caution is advised if loxapine is combined with other medicinal products known to lower the seizure threshold
Magnesium hydroxide, phenothiazines
The magnesium hydroxide may decrease the absorption of phenothiazine. Separate administration by 2-3 hours
Magnesium, phenothiazines ---> SmPC of [levomepromazine] of eMC
The co-administration may decrease the absorption of phenothiazine. Separate administration by at least 2 hours
Maprotiline, phenothiazines
The co-administration may increase the plasma levels of maprotiline, decrease the seizure threshold and cause seizures
Mefloquine, phenothiazines
Concomitant administration of mefloquine and other drugs known to alter cardiac conduction might contribute to a prolongation of the QTc interval.
Mefruside, phenothiazines
The co-administration may increase the antihypertensive effects
Meglumine and sodium ioxitalamate, phenothiazines
Medicinal products that reduce the convulsant threshold should be discontinued 48 hours before and up to 24 hours after examination
Mephenytoin, phenothiazines
Increased hydantoin plasma levels
Meprobamate, phenothiazines [2] ---> SmPC of [2] of eMC
Like barbiturates, meprobamate can cause induction of liver enzymes, so that the availability and blood levels of drugs given concurrently that are metabolised in the liver may be affected.
Metformin, phenothiazines
Decreased hypoglycemic effect
Methadone [1], phenothiazines ---> SmPC of [1] of eMC
The depressant effects of methadone are likely to be enhanced by depressants of the CNS. As well as CNS depression, there may be respiratory depression and/or hypotension.
Methoxsalen, phenothiazines
The co-administration of methoxsalen with photosensitizing agents should be done with caution
Methyldopa, phenothiazines
Methyldopa increases the risk of extrapyramidal side effects with phenothiazines.
Metoclopramide, phenothiazines [2] ---> SmPC of [2] of eMC
Coadministration of phenothiazines with metoclopramide increases the risk of extrapyramidal effects.
Metrizamide, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may predispose to metrizamide-induced seizures.
Morphine [1], phenothiazines ---> SmPC of [1] of eMC
Morphine sulphate potentiates the effects of other central nervous depressants
Moxifloxacin [1], phenothiazines ---> SmPC of [1] of eMC
The co-administration may have an additive effect on the QT interval prolongation. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. The combination is contraindicated.
Muscle relaxants, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may enhance the absorption of neuromuscular blocking agents.
Nalbuphine, phenothiazines
The co-administration may potentiate the fatigue and vomiting
Nebivolol [1], phenothiazines ---> SmPC of [1] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Non-potassium-sparing diuretics, phenothiazines
Diuretic-induced hypokalaemia may potentiate phenothiazine-induced cardiotoxicity.
Noradrenaline, phenothiazines
The co-administration of noradrenaline with phenothiazines may decrease the hypertensive effect of noradrenaline
Norephedrine, phenothiazines
The co-administration may cause ventricular arrhythmias
Norepinephrine, phenothiazines
The co-administration of noradrenaline with phenothiazines may decrease the hypertensive effect of noradrenaline
Norfenefrine, phenothiazines
The co-administration may weaken the sympathomimetic effect
Norpseudoephedrine, phenothiazines
Total or partial suppression of the central stimulant and anorexigenic of cathine by neuroleptic drugs
Opipramol, phenothiazines
Tricyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Oral antidiabetics, phenothiazines ---> SmPC of [fluphenazine] of eMC
Phenothiazines may impair the control of diabetes.
Oral contraceptives, phenothiazines
The co-administration of oral contraceptive may inhibit the metabolism of phenothiazines, what may enhance the effects and adverse reactions
Orphenadrine, phenothiazines
Potentiation of anticholinergic effect
Oxomemazine, phenothiazines
Enhancement of central anticholinergic effect
Oxprenolol, phenothiazines
The co-administration may enhance the hypotensive effect
Oxybutynine [1], phenothiazines ---> SmPC of [1] of EMA
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity
Oxycodone [1], phenothiazines ---> SmPC of [1] of eMC
Central nervous system depressants can enhance the adverse reactions of oxycodone, in particular respiratory depression.
Padeliporfin [1], phenothiazines ---> SmPC of [1] of EMA
Medicinal products which have potential photosensitising should be stopped at least 10 days before the procedure with TOOKAD and for at least 3 days after the procedure or replaced by other treatments without photosensitizing properties.
Paliperidone [1], phenothiazines ---> SmPC of [1] of EMA
Caution is advised if paliperidone is combined with other medicines known to lower the seizure threshold
Paroxetine [1], phenothiazines ---> SmPC of [1] of eMC
Caution is advised in patients taking SSRIs, concomitantly with oral anticoagulants, drugs known to affect platelet function or increase risk of bleeding
Pentamidine [1], phenothiazines ---> SmPC of [1] of eMC
Caution is advised when pentamidine isetionate is concomitantly used with drugs that are known to prolong the QT interval
Pentazocine [1], phenothiazines ---> SmPC of [1] of eMC
Agents with sedative action can enhance the central depressant effects of pentazocine
Pentetrazol, phenothiazines
Seizures
Pergolide [1], phenothiazines ---> SmPC of [1] of eMC
The action of pergolide may be opposed by phenothiazine neuroleptics
Perindopril, phenothiazines
The co-administration may cause postural hypotension
Pethidine [1], phenothiazines ---> SmPC of [1] of eMC
Severe hypotension may occur when pethidine is administered to patients whose ability to maintain blood pressure has been compromised (e. g. by phenothiazines)
Phenothiazines [1], procarbazine ---> SmPC of [1] of eMC
Procarbazine may enhance the effect of drugs with anticholinergic effects
Phenothiazines, phenylpropanolamine
Phenylpropanolamine has been reported to interact with phenothiazines and cause ventricular arrhythmias.
Phenothiazines, phenytoin [2] ---> SmPC of [2] of eMC
Phenothiazines may increase phenytoin serum levels
Phenothiazines, pholcodine
Pholcodine may enhance the sedative effect of central nervous system depressants
Phenothiazines, pimozide [2] ---> SmPC of [2] of eMC
Concomitant use of pimozide with drugs known to prolong the QT interval is contra-indicated
Phenothiazines, pindolol
Concomitant use of beta-blockers with phenothiazines may increase the blood pressure lowering effect.
Phenothiazines, pindolol/clopamide
Concomitant use of pindolol/clopamide and phenothiazines may increase the blood pressure lowering effect.
Phenothiazines, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA
Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur
Phenothiazines, piperaquine ---> SmPC of [piperaquine/artenimol] of EMA
The combination of piperaquine with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval
Phenothiazines, piperaquine/artenimol [2] ---> SmPC of [2] of EMA
The combination of piperaquine/dihydroartemisinin with drugs that are known to prolong the QTc interval is contraindicated: additive effect on the QTc interval
Phenothiazines, piperidolate
The co-administration may increase the risk of adverse effects, e.g. paralytic ileus, retention of urine and blurred vision
Phenothiazines, piretanide
The hypotensor effect of piretanide may be potentiated
Phenothiazines, piritramide
The co-administration may enhance the adverse effects of piritramide, particularly respiratory depression
Phenothiazines, polypeptide antibiotics
Phenothiazines may enhance a central respiratory depression in conjunction with polypeptide antibiotics
Phenothiazines, porfimer [2] ---> SmPC of [2] of EMA
It is possible that concomitant use of other photosensitising agents could increase the photosensitivity reaction.
Phenothiazines, prazepam
Concomitant use of prazepam and other CNS depressant drugs can mutually enhance the effects
Phenothiazines, procyclidine [2] ---> SmPC of [2] of eMC
Drugs with anticholinergic properties may increase the anticholinergic action
Phenothiazines, promazine [2] ---> SmPC of [2] of eMC
Concomitant use of promazine with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore, concomitant use of these products is not recommended.
Phenothiazines, propiverine [2] ---> SmPC of [2] of eMC
Increased effects of propiverine due to concomitant medication with neuroleptics (e. g. phenothiazines)
Phenothiazines, QT interval prolonging drugs
Phenothiazines increase the risk of ventricular arrhythmias when given with drugs which prolong the QT interval
Phenothiazines, quinidine
The phenothiazine may enhance the cardiodepressant effect of quinidine
Phenothiazines, risperidone [2] ---> SmPC of [2] of eMC
Phenothiazines may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.
Phenothiazines, rotigotine [2] ---> SmPC of [2] of EMA
Because rotigotine is a dopamine agonist, it is assumed that dopamine antagonists, such as neuroleptics or metoclopramide, may diminish the effectiveness of rotigotine, and co-administration should be avoided.
Phenothiazines, roxithromycin
Caution is warranted for concomitant use of roxitromycin with other QT interval prolonging medicines
Phenothiazines, saquinavir/ritonavir ---> SmPC of [saquinavir] of EMA
The combination is contraindicated due to the potential for life threatening cardiac arrhythmia
Phenothiazines, scopolamine
Scopolamine may enhance the anticholinergic effect
Phenothiazines, seizure-threshold lowering drugs
Caution is advised when concomitantly using medicinal products capable of lowering the seizure threshold
Phenothiazines, sertraline [2] ---> SmPC of [2] of EMA
Caution is advised in patients taking SSRIs, particularly in concomitant use with drugs known to affect platelet function
Phenothiazines, sotalol [2] ---> SmPC of [2] of eMC
Sotalol should be given with extreme caution in conjunction with other drugs known to prolong the QT-interval. Drugs that prolong the QT-interval may cause torsades de pointes. The co-administration with sotalol is contraindicated
Phenothiazines, SSRI ---> SmPC of [fluphenazine] of eMC
There have been rare reports of acute Parkinsonism when an SSRI has been used in combination with a phenothiazine.
Phenothiazines, succinylcholine
The co-administration may enhance the neuromuscular blocking action of suxamethonium
Phenothiazines, sulfonylureas
Weakening of the blood-glucose-lowering effect and possible hyperglycaemia
Phenothiazines, suxamethonium
The co-administration may enhance the neuromuscular blocking action of suxamethonium
Phenothiazines, sympathomimetics ---> SmPC of [fluphenazine] of eMC
Phenothiazines may antagonise the action of sympathomimetic agents
Phenothiazines, talinolol
The co-administration may cause a pronounced hypotension
Phenothiazines, telithromycin [2] ---> SmPC of [2] of EMA
Due to a potential to increase the QT interval, telithromycin should be used with care during concomitant administration with QT interval prolonging agents
Phenothiazines, tetrabenazine
Coadministration of phenothiazines with tetrabenazine increases the risk of extrapyramidal effects.
Phenothiazines, tetrazepam
The co-administration may mutually enhance the CNS depressant effects
Phenothiazines, thiazides
The co-administration of phenothiazines with diuretic thiazides may cause severe hypotension.
Phenothiazines, thiethylperazine
The co-administration may potentiate the CNS depressant effect
Phenothiazines, timolol [2] ---> SmPC of [2] of eMC
Concomitant administration of timolol with phenothiazines may increase the blood pressure lowering effect.
Phenothiazines, toremifene [2] ---> SmPC of [2] of EMA
An additive effect on QT interval prolongation between toremifene and medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias. Co-administration is contraindicated
Phenothiazines, trazodone [2] ---> SmPC of [2] of eMC
Severe orthostatic hypotension has been observed in case of concomitant use of trazodone und phenothiazines
Phenothiazines, tretinoin
Concomitant use of tretinoin crème with photosensitizers should be avoided
Phenothiazines, triamterene
The co-administration of triamterene and phenothiazines may enhance the hypotensive effect
Phenothiazines, triamterene/hydrochlorothiazide
The antihypertensive effect of triamterene/hydrochlorothiazide may be enhanced by phenothiazines
Phenothiazines, tricyclic antidepressant
The coadministration may increase the plasma levels of tricyclic antidepressants and/or phenothiazines. It has been reported that the co-administration may result in heart rhythm disorders
Phenothiazines, trihexyphenidyl
Extra care should be taken when trihexyphenidyl is given concomitantly with phenothiazines because of the possibility of increased antimuscarinic side-effects.
Phenothiazines, tropicamide
Enhancement of anticholinergic effect
Phenothiazines, tryptophan
The co-administration may cause sexual disinhibition, reversible dyskinesia and parkinsonian symptoms
Phenothiazines, vasoconstrictors
Decreased hypertensive effect of vasoconstrictor
Phenothiazines, vasopressor sympathomimetics ---> SmPC of [thioridazine] of eMC
Owing to their adrenolytic action, phenothiazines may reduce the pressor effect of adrenergic vasoconstrictors (i.e. ephedrine, phenylephrine).
Phenothiazines, verteporfin [2] ---> SmPC of [2] of EMA
It is possible that concomitant use of other photosensitizing medicinal products could increase the potential for photosensitivity reactions. Caution should be exercised
Phenothiazines, vortioxetine [2] ---> SmPC of [2] of EMA
Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold
Phenothiazines, xipamide [2] ---> SmPC of [2] of eMC
The combination increases the risk of ventricular arrhythmias, particularly torsades de pointes (favored by hypokaliemia). It is recommended a special caution
Phenothiazines, xylometazoline
Xylometazoline should not be used, when the patient is treated with phenothiazines